Digital Biomanufacturing Market Revenue to Cross USD 12 billion by 2035 | Roots Analysis

Digital biomanufacturing encompass a diverse array of technologies, including process analytical technology (PAT), data analysis software (DAS), manufacturing execution systems (MES) and digital twins used to achieve operational excellence, visibility, control and synchronization in bioprocessing with an aim to produce better yield in faster timelines. 

Digital biomanufacturing employs various digital manufacturing principles, such as computer-aided design, real-time monitoring and process validation, to facilitate improvement in the overall biological manufacturing process. The increased demand for biologics and challenges in handling complex datasets have spurred a requirement for digitally integrated solutions. 

These solutions streamline end-to-end operations, optimizing bioprocessing. The emergence of digital biomanufacturing holds promise as a viable alternative to address various concerns in bioprocessing. It also plays a significant role in enhancing process robustness and ensuring product quality.

The global digital biomanufacturing market size was estimated at USD 1.7 billion in 2023 and is expected to reach over USD 12.3 billion by 2035, growing at a CAGR of 18% in the forecast period 2023-2035. 

Market Drivers 

Several factors are propelling the growth of the digital biomanufacturing market. The extensive use of conventional biomanufacturing operations has put significant pressure on the biopharmaceutical industry to achieve high yield and high quality in biologics production in shorter time duration.  

The digital biomanufacturing solutions have emerged as a promising alternative over these traditional manufacturing processes owing to their various benefits such as real-time performance analysis, informed data-driven decisions, and low batch-to-batch variability. Given the potential of digital biomanufacturing it is worth highlighting that digitalization in biomanufacturing is becoming  an essential requirement.  

Market Restraints 

While the digital biomanufacturing market is experiencing substantial growth, it is not without its challenges. One of the primary restraints is the high cost associated with various technologies and infrastructure required for digital biomanufacturing. The biopharmaceutical sector faced challenges in implementing technologies like artificial intelligence, machine learning, internet of things, and cloud computing. 

Further, players offering digital biomanufacturing technology possess large amounts of data, including sensitive information, and hence, might face privacy and security risks. Moreover, despite the significant increase in the adoption of digital technologies in biologics manufacturing in recent years, the biopharmaceutical industry has not fully embraced these advancements. 

Additionally, a lack of technical knowledge in the field of digital biomanufacturing prevents organizations from implementing digital solutions. The gaps in understanding and familiarity with digitalization pose challenges to the widespread deployment of these technologies across all levels of the organization.

Growth Factors 

Despite the challenges, several growth factors continue to drive the digital biomanufacturing market forward. Given the exponential rise in the approvals received by biologics in past few years, companies have realized that innovation in this field is required in order to cater the need of this rising demand for quality biologics.

Further, stakeholders are proactively taking initiatives to embrace advanced technologies offered by digital biomanufacturing upon recognizing the potential of digital biomanufacturing over traditional methods. The aim of the companies is to enhance operational excellence, visibility, control, and synchronization in the realm of bioprocessing. 

As a result, the digital biomanufacturing market is poised to offer lucrative opportunities for technology providers in the coming years as efforts continue to overcome inefficiencies in conventional biologics manufacturing.

Market Segments 

Based on the type of technology, the market is segmented into process analytical technology (PAT), data analysis software (DAS), manufacturing execution systems (MES) and digital twins. 

The process analytical technology (PAT) segment led the market for digital biomanufacturing, capturing the largest revenue share of close to 35.0% in 2023.

The digital twins segment is anticipated to show the highest growth potential during the forecast period of over 27% annually.

Based on the deployment options, the market is segmented into cloud-based and on-premises.

The on-premises segment led the market for digital biomanufacturing, capturing the largest revenue share of more than 70.0% in 2023.

The cloud-based segment is anticipated to show the highest growth potential during the forecast period of over 23% annually.

Based on the type(s) of biologic(s) manufactured, the market is segmented into antibodies, cell and gene therapies, proteins, vaccines and others.

The antibodies segment led the market for digital biomanufacturing, capturing the largest revenue share of more than 40.0% in 2023.

The proteins, cell and gene therapies segment is anticipated to show the highest growth potential during the forecast period of close to 20% annually.

Based on the Regional Insights, the digital biomanufacturing market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & North Africa

Europe dominated the digital biomanufacturing market and accounted for the largest revenue share of about 38.0% in 2023.

In Asia-Pacific, the digital biomanufacturing market is anticipated to demonstrate lucrative growth during the forecast period.

Key Companies Profiled 

The digital biomanufacturing market report also includes detailed profiles of key players (listed below) that offer digital biomanufacturing:

§  AspenTech

§  Bioreactors.net

§  Dassault Systèmes

§  FUJIFILM Diosynth Biotechnologies

§  GE Healthcare

§  Körber

§  Merck

§  Sartorius

§  Thermo Fisher Scientific

About Roots Analysis

Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. All reports provided by us are structured in a way that enables the reader to develop a thorough perspective on the given subject. Apart from writing reports on identified areas, we provide bespoke research / consulting services dedicated to serve our clients in the best possible way.

Contact Details

Gaurav Chaudhary

+1 (415) 800 3415

+44 (122) 391 1091

Email: sales@rootsanalysis.com